BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/26/2026 5:51:08 AM | Browse: 2 | Download: 0
 |
Received |
|
2025-12-11 02:28 |
|
Peer-Review Started |
|
2025-12-11 02:28 |
|
First Decision by Editorial Office Director |
|
2026-01-07 10:05 |
|
Return for Revision |
|
2026-01-09 07:06 |
|
Revised |
|
2026-01-20 10:06 |
|
Publication Fee Transferred |
|
2026-01-22 09:40 |
|
Second Decision by Editor |
|
2026-03-05 02:44 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-03-05 08:03 |
|
Articles in Press |
|
2026-03-05 08:03 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-03-19 06:39 |
|
Publish the Manuscript Online |
|
2026-03-26 05:51 |
| ISSN |
1949-8470 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, General & Internal |
| Manuscript Type |
Retrospective Study |
| Article Title |
Predictive model for vedolizumab efficacy in moderate-to-severe ulcerative colitis based on computed tomography-derived body compositions and nutritional inflammatory markers
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xiao-Yan Zhang, Yu-Kun Li, Zi-Bin Tian, Qing-Yu Guo, Jing-Nong Liu, Rui-Qing Liu and Ke-Yu Ren |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ke-Yu Ren, Department of Gastroenterology, The Affiliated Hospital of Qingdao University, No. 1677 Wutaishan Road, Qingdao 266000, Shandong Province, China. renkeyuqd@126.com |
| Key Words |
Ulcerative colitis; Vedolizumab; Therapeutic response; Inflammatory markers; Body composition |
| Core Tip |
Combined assessment of intramuscular adipose tissue, C-reactive protein levels, skeletal muscle mass and hemoglobin status can effectively predict vedolizumab response in ulcerative colitis patients. Routine screening of these markers helps identify potential non-responders early, optimize individualized treatment regimens, and improve clinical management efficiency of ulcerative colitis. |
| Publish Date |
2026-03-26 05:51 |
| Citation |
Zhang XY, Li YK, Tian ZB, Guo QY, Liu JN, Liu RQ, Ren KY. Predictive model for vedolizumab efficacy in moderate-to-severe ulcerative colitis based on computed tomography-derived body compositions and nutritional inflammatory markers. World J Radiol 2026; 18(3): 117599 |
| URL |
https://www.wjgnet.com/1949-8470/full/v18/i3/117599.htm |
| DOI |
https://dx.doi.org/10.4329/wjr.v18.i3.117599 |
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
